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The U.S. Preventive Services Task Force (USPSTF) recently updated their national lung screening guidelines and recommended
low-dose computed tomography (LDCT) for lung cancer (LC) screening through age 80. However, the risk of overdiagnosis
among older populations is a concern. Using four comparative models from the Cancer Intervention and Surveillance Modeling
Network, we evaluate the overdiagnosis of the screening program recommended by USPSTF in the U.S. 1950 birth cohort. We
estimate the number of LC deaths averted by screening (D) per overdiagnosed case (O), yielding the ratio D/O, to quantify the
trade-off between the harms and benefits of LDCT. We analyze 576 hypothetical screening strategies that vary by age, smok-
ing, and screening frequency and evaluate efficient screening strategies that maximize the D/O ratio and other metrics includ-
ing D and life-years gained (LYG) per overdiagnosed case. The estimated D/O ratio for the USPSTF screening program is 2.85
(model range: 1.5–4.5) in the 1950 birth cohort, implying LDCT can prevent ~3 LC deaths per overdiagnosed case. This D/O
ratio increases by 22% when the program stops screening at an earlier age 75 instead of 80. Efficiency frontier analysis
shows that while the most efficient screening strategies that maximize the mortality reduction (D) irrespective of overdiagno-
sis screen through age 80, screening strategies that stop at age 75 versus 80 produce greater efficiency in increasing life-
years gained per overdiagnosed case. Given the risk of overdiagnosis with LC screening, the stopping age of screening merits
further consideration when balancing benefits and harms.
The National Lung Screening Trial (NLST) recently demon-
strated that low-dose computed tomography (LDCT) is effec-
tive in reducing lung cancer (LC) mortality.1 However,
overdiagnosis of LC in LDCT screening is a significant con-
cern.2–4 Overdiagnosis is defined as the screen-detected dis-
ease that in the absence of screening, would not have become
clinically evident within one’s lifetime.5 Overdiagnosis can
lead to unnecessary treatment and costs and negatively
impact well-being and life expectancy.5
The Cancer Intervention and Surveillance Modeling Net-
work (CISNET) is a National Cancer Institute (NCI) spon-
sored consortium that uses a comparative statistical modeling
approach to estimate the population-level impact of cancer
screening. In prior work, the CISNET lung cancer screening
models were used to evaluate the comparative effectiveness of
576 screening strategies that varied by smoking history, age,
and screening frequency.6–8 These analyses were used by the
U.S. Preventive Services Task Force (USPSTF) as secondary
evidence to support the recent recommendation to annually
screen persons aged 55 to 80 with the same smoking criteria
as the NLST.9 One notable aspect of the USPSTF recommen-
dation is the increased stopping age to 80 from 74 compared
to the NLST. Although several harms (including overdiagno-
sis) were considered by the USPSTF, harms were not explicit-
ly incorporated when ranking the efficient scenarios provided
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by CISNET; instead these scenarios were selected by maxi-
mizing the LC mortality reduction, i.e. the number of LC
deaths (D) prevented due to screening over the number of
CT screening examinations.7
While the lung cancer screening guidelines by USPSTF
recommended LDCT targeting the age group of 55 to 80,
there is still considerable debate over the potential benefits
and harms of screening in the older population. The Centers
for Medicare & Medicaid Services (CMS) issued a national
coverage determination for Medicare coverage of LDCT
screening for individuals aged 55 to 77 (www.cms.gov)
whereas the USPSTF recommends screening up to age 80.
Other guidelines such as those proposed by the American
Cancer Society (ACS) recommended CT screening for indi-
viduals ages 55 to 74.10 Hence, the stopping age of screening
varies widely across different guidelines (ages 74, 77, 80)
while the starting age (age 55) and smoking criteria (30
pack-years and 15 years since cessation) are consistent across
recommendations. Not surprisingly, the age of LC patients
also has shown to be associated with increased risk of post-
operative complications: patients aged 50 to 69 have a three-
fold higher risk for life-threatening complications compared
to patients aged <50, while the risk is a ninefold higher for
patients aged >70.11 Given the importance of the effect of
screening age on the potential harms and the divergence on
the recommended stopping for lung screening, it is essential
to evaluate the optimal stopping age of lung cancer screening
by more directly accounting for screening-associated harms.
In this study, CISNET re-examines efficient screening
strategies for lung cancer using a range of metrics that incor-
porate overdiagnosis. One useful metric for assessing the
impact of overdiagnosis is the ratio between LC deaths pre-
vented due to screening (D) and overdiagnosed cases (O),
represented by D/O. This metric has been previously used to
quantify the trade-off between the harms and benefits of
screening.5 Other measures are also considered such as life-
years gained (LYG) due to screening and the LYG per over-
diagnosed case (LYG/O). We use four independent CISNET
lung models to estimate LC overdiagnosis for 576 alternative
CT screening scenarios that vary by smoking, age, and
screening frequency in the general U.S. population. Included
is the direct comparison between the USPSTF recommended
scenario and the NLST-like scenario (i.e. ACS-like scenario),
which only differ in the screening stopping age (80 vs. 75).
We evaluate screening strategies that optimize a range of
metrics integrating overdiagnosis, comparing their outcomes
to those based on LC mortality reduction (D) alone. These
findings can provide insights into the impact of incorporating
overdiagnosis on the selection of efficient lung screening pro-
grams, providing a more balanced consideration of screening
benefits and harms.
Methods
CISNET models
Four CISNET LC screening models were independently
developed based on different sets of assumptions and mathe-
matical model structures at the following institutions: Eras-
mus Medical Center; Fred Hutchinson Cancer Research
Center; the Massachusetts General Hospital, and Stanford
University. The common model components are: age-specific
LC risk in the absence of screening, natural history model for
tumor growth and progression, screening component for pre-
dicting detection age and stage of LC in the presence of
screening, diagnostic workup component for following up
lung nodules; and corresponding LC mortality and death
from other causes6–8(see Supporting Information Table 1).
Each model was calibrated and validated using the data
from NLST and PLCO (Prostate, Lung, Colorectal, and Ovar-
ian Cancer Screening)6,12 to obtain estimates on screening-
related parameters such as tumor size thresholds for diagnos-
tic follow-up. Each model reproduced the observed incidence
and mortality of LC (stratified by cancer stage at diagnosis,
histology, sex, and detection mode) in both arms of these
trials.6
Target population and screening scenarios
The models were used to simulate life histories of the U.S.
cohort born in 1950, whose smoking histories and other-
cause mortalities were generated using the Smoking History
Generator.13 We chose the 1950 birth cohort because it was
considered in the USPSTF report.9 We evaluated a total of
576 screening scenarios, varying the frequency of screening
(annual, biennial, or triennial), starting age (45, 50, 55, or
60), stopping age (75, 80, or 85), minimum pack-years of
smoking (25, 30, 35, or 40) and maximum years since quit-
ting smoking (5, 10, 15, or 20) as considered in our previous
reports.7,8
Each model was run for each of 576 screening strategies,
assuming perfect screening compliance. For each strategy,
each model produced several population-level outcomes,
What’s new?
Screening high-risk patients for lung cancer clearly saves lives. However, treatment has its own risks, especially for cancers
that would not have affected the patient’s health during their lifetime. Clinicians thus need guidance in order to achieve a bal-
ance between screening to reduce mortality, and the risks and excess costs associated with overdiagnosis. In this study, the
authors found that when screening is stopped at age 75 and above, it provides greater efficiency in reducing deaths due to
lung cancer per overdiagnosed case.
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including number of LC deaths, number of LDCT screening
examinations, number of prevented LC deaths (D) and life-
years gained (LYG) due to screenings compared to a no-
screening scenario. All counts were normalized per 100,000
persons in the cohort, who are followed up from age 45 to
90. False positives, radiation-related harms, and follow-up
examinations were also previously quantified by some of the
models.7
Quantification of overdiagnosis
A patient is defined as overdiagnosed if their LC is detected
in the screening scenario, but the tumor would not have
been clinically detected before death from other causes in the
no-screen scenario. We calculated a measure of overdiagnosis
as the probability that a lung cancer detected by screening is
an overdiagnosis. Using each simulation model, the risk of
overdiagnosis was calculated as the number of overdiagnosed
cases divided by the number of screen-detected cases, i.e., the
proportion of screen-detected cases that are overdiagnosed.
We compared overdiagnosis risk of 576 strategies stratified
by screening starting/stopping age, smoking (pack-year and
year-since-quit), gender or histology. To compare the esti-
mated median overdiagnosis risk by groups, we applied the
non-parametric Kruskal-Wallis (K-W) test. D/O was calculat-
ed by dividing the number of LC deaths prevented due to
screening by the number of overdiagnosed cases.
Selection of consensus scenarios
For each model, we selected a series of scenarios that maxi-
mize the D/O ratio over the number of screening examina-
tions by identifying the convex hull on a scatter plot between
the D/O ratio (y-axis) and the number of CT screens (x-
axis).7 An efficient frontier is defined as this convex hull, that
is, a curve that connects a set of scenarios that maximize the
y-values over x-values. A scenario was labeled as an “efficient
scenario” if it is among the top 25% closest scenarios to the
efficiency frontier. A set of consensus scenarios was identified
by choosing scenarios that are defined as an “efficient
scenario” by at least three out of the four models.
We selected consensus scenarios by maximizing the D/O
ratio and, separately D, as a function of the number of
screening examinations, by sex. In selecting efficient and con-
sensus scenarios for both metrics, we focused on annual
screening scenarios with starting age 55 and stopping age
80, since they are considered to be the most feasible for
implementation. When analyzing the findings, we focused on
the scenarios that are near the NLST and USPSTF scenarios,
associated with the number of CT screens ranging between
250,000 and 350,000 (per 100,000 persons in the cohort) for
males and 160,000 and 260,000 for females.
In a sensitivity analysis, we considered several alternative
metrics that incorporate overdiagnosis to examine how the
selection of efficient and consensus scenarios is affected by
using different metrics. First, we considered LYG instead of
D. While LYG takes into account different life expectancy
among LC cases when measuring the benefit of screening, it
does not explicitly incorporate overdiagnosis. Therefore, we
also considered LYG/O as a metric for selecting efficient
screening strategies. Another alternative metric that incorpo-
rate overdiagnosis is defined as D-O, which is the net pre-
vented LC deaths subtracted by the number of overdiagnosed
cases; this metric measures the benefit of screening (D)
penalized by overdiagnosis (O). The last metric that was con-
sidered is defined as D/(O/S), the number of LC deaths pre-
vented per overdiagnosis risk, where S is the number of
screen-detected cases.
Results
The calibration results of the four models using the NLST
data are shown in Supporting Information Figure 1. This fig-
ure shows that the four models reliably reproduce the out-
comes of the NLST data, in which the model-based estimates
for excess LC incidence rate in the CT arm compared to the
chest X-ray arm are consistent with the reported value of
18.5% (95% confidence interval 5.5–30.6%) based on the
NLST data.2
Overdiagnosis risk across 576 LC screening strategies
The analysis of 576 screening scenarios indicates that the
overdiagnosis risk is highly influenced by screening stopping
age. Figures 1a to 1d display the results for males, in which
the screening programs with stopping age 85 have higher
overdiagnosis rates (model median range: 5.51–16.44%) than
the programs with lower stopping ages (model median range:
3.91–10.72% for stopping age 75 and 4.73–13.71% for stop-
ping age 80). These patterns are similar for females and
across the four models with all p values of the eight K-W
tests <10210. The comparisons of overdiagnosis risks by
screening frequency, starting age, and pack-years of smoking
are presented in Supporting Information Materials S1 and
Supporting Information Figures 2 to 4. In these analyses, we
find overdiagnosis is higher for more frequent screening,
older starting age, and higher smoking pack-years. Among
histologic subtypes, BAC (bronchioloalveolar carcinoma) has
the highest overdiagnosis risk.
Comparisons of the USPSTF and NLST-like scenarios
Comparisons of the USPSTF and the NLST-like scenarios
(Figs. 2a–2c) show that overdiagnosis risk is higher for the
USPSTF scenario (mean: 11.9%; model range: 5.5–23.2%)
than the NLST-like scenario (mean: 9.7%; model range: 4.4–
17.6%) by 21.7% (model range for percentage increase: 10–
31.8%) due to the extended stopping age. This pattern is con-
sistently observed across the models for each gender. The
analysis of the D/O ratio (Figs. 2d–2f and Supporting Infor-
mation Table 2) shows that the USPSTF scenario prevents
2.85 LC deaths per overdiagnosed case (mean D/O
ratio5 2.85; model range: 1.5–4.5). Notably, the D/O ratio
increased by 22% when the program stops screening at an
earlier age 75 instead of 80 as shown in the NLST-like
C
an
ce
r
E
pi
de
m
io
lo
gy
2438 Overdiagnosis and lung cancer screening
Int. J. Cancer: 140, 2436–2443 (2017) VC 2017 UICC
scenario (mean: 3.49, model range: 2.10–5.61). The range of
D/O ratios of all 576 scenarios are shown in Supporting
Information Table 3 by model and gender.
Consensus scenarios
The scenarios that maximize D over the numbers of CT screens
among males are shown in Figure 3(a), plotted for a represen-
tative model, with all other model results for both genders
shown in Supporting Information Figures 5 and 6. It is notable
that all the consensus scenarios have stopping age 80 (instead
of 75), which reflects the greater efficiency of programs that
screen through older age 80, as opposed to 75, for reducing the
number of LC deaths. Notably, the consensus scenarios include
the USPSTF scenario (A-55–80-30–15). Other measures of ben-
efits of LDCT for the consensus scenarios such as life-years and
mortality reduction rate are shown in Table 1.
The consensus scenarios that maximize D/O over the
number of CT screens are shown in Figure 3(b). Interesting-
ly, all the consensus scenarios maximizing D/O have stopping
age 75, instead of 80, which suggests that programs that stop
screening earlier are more efficient in reducing the number
of LC deaths per overdiagnosed case. Notably, the NLST-like
scenario (A-55–75-30–15) is included among the consensus
scenarios selected by four models for each gender.
The gray colored scenarios in Table 1 are consensus sce-
narios that overlap across genders within each metric for D
and D/O. Overall, higher consensus was observed using the
metric D/O across genders, where 80% of all the consensus
scenarios (four of five) are selected in both genders while for
metric D, around 44% of all consensus scenarios (four of
nine) appear in both genders.
Sensitivity analysis to outcomes metric
The selection of consensus scenarios using LYG instead of D
is shown in Figure 3(c), which is similar to the selection
under D in the sense that both sets of consensus scenarios
include the USPSTF scenario. However, a tendency was
observed that using LYG (vs. d) penalizes screening through
older ages; while all consensus scenarios chosen under D
screen through 80, the consensus scenarios using LYG
includes a scenario that stops screening at 75 (A-55–75-30–
20). When overdiagnosis is taken into account by using
LYG/O, however, the selection of consensus scenarios was
remarkably similar to those using D/O (see Fig. 3d).
Further sensitivity analyses using alternative outcomes met-
rics, namely D-O and D/(O/S), show that the consensus scenari-
os that incorporate overdiagnosis are consistent with the ones
selected by maximizing D/O (Figs. 3e and 3f). Most of the
Figure 1. Overdiagnosis risk (%) of 576 scenarios by stopping age of screening programs for each model and gender. Overdiagnosis risk is
calculated as the number of overdiagnosed cases divided by the number of screen-detected cases. The number for each box represents a
median of overdiagnosis risk of screening programs with given stopping age. “KW” denotes Kruskal-Wallis (K-W) test. [Color figure can be
viewed at wileyonlinelibrary.com]
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consensus scenarios have stopping age 75 (except for one scenar-
io) and the NLST-like scenario is included among the consensus
scenarios. Using the metric D-O (Fig. 3e), four out of the five
consensus scenarios are shown to be selected as consensus sce-
narios using the metric D/O (Table 1). Using the outcomes met-
ric D/(O/S) (Fig. 3f), four out of the five consensus scenarios also
appear in the list selected using the metric D/O (Table 1).
Discussion
We presented a comparative model-based analysis of overdi-
agnosis in lung cancer screening by quantifying the trade-off
between harms and benefits of LDCT. Our analysis shows
that the lifetime screening program recommended by the
USPSTF can prevent approximately three LC deaths by per
overdiagnosed case (mean D/O ratio5 2.85). The D/O ratio
increases by 22% when the program stops screening at an
earlier age 75 instead of 80, as shown in the NLST-like sce-
nario (mean D/O ratio5 3.49). Given that the USPSTF sce-
nario prevents more LC deaths than the NLST-like scenario
(i.e. a larger value of D in the USPSTF scenario), the lower
D/O of the USPSTF scenario implies that the number of
overdiagnosed cases (O) increases more quickly than the
number of LC deaths prevented (D) as screening is extended
to the older ages. Overall, overdiagnosis was significantly
associated with increased screening stopping age in our anal-
ysis of 576 hypothetical screening strategies (p< 10210).
The efficiency frontier analysis shows that the most effi-
cient screening strategies that maximize the outcomes metrics
incorporating overdiagnosis, namely D/O, LYS/O, D-O, and
D/(O/S), are consistently the strategies that stop screening at
age 75 (which include the NLST-like scenario) compared to
programs that screen through age 80. On the other hand,
efficient programs chosen based on maximizing the number
of LC deaths prevented (D) irrespective of overdiagnosis are
the ones that screen through 80, which includes the USPSTF
recommendation. While previous model-based studies con-
sidered mortality reduction (D) when identifying efficient
screening strategies14–16 including our earlier work,7,8 we
examined the impact of incorporating overdiagnosis on the
selection of efficient scenarios by investigating various metrics
that integrate overdiagnosis. Undoubtedly there are other
useful metrics to more explicitly quantify the harms associat-
ed with overdiagnosis such as quality-adjusted life-years
(QALY); such metrics were not used in the current study
because we intended our analysis to be directly comparable
to the recent CISNET analyses performed for the USPSTF,7,9
which used D, not QALY, in ranking the efficient scenarios.
A noteworthy aspect in the analysis of the D/O ratios for
576 screening strategies is that in most scenarios (99%), the
D/O values are larger than one (i.e. D/O> 1) across the four
models. This finding implies that the number of LC deaths
prevented by screening is greater than the number of
Figure 2. Comparisons of overdiagnosis risks and D/O ratios (the number of LC deaths prevented per overdiagnosed case) of the USPSTF
and the NLST-like scenarios, by gender and both genders combined. Overdiagnosis risk is calculated as the number of overdiagnosed cases
divided by the number of screen-detected cases.
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Figure 3. Consensus screening scenarios chosen for males by maximizing: (i) D, the number of LC deaths prevented (a); (ii) D/O, the num-
ber of LC deaths prevented per overdiagnosed case (b); (iii) life-years gained (LYG) (c); (iv) life-year gained per overdiagnosed case (LYG/O)
(d); (v) D-O, net LC deaths prevented subtracting overdiagnosed cases (e); (vi) and D/(O/S), the number of LC deaths prevented per overdi-
agnosis risk (f), where S is the number of screen-detected cases. In each figure, we show the outcomes under several screening strategies
that vary by age and smoking eligibility criteria. Each dot represents a specific screening strategy, with selected scenarios highlighted in
color. Here, the x-axis is the number of CT screens that need to be performed under each strategy. (a) The number of LC deaths avoided
versus no-screening (D, y-axis) under the given strategy. (b–f) show alternative outcome metrics: LC deaths avoided per overdiagnosed
case (D/O, b), life-years gained (LYG, c), life-years gained per overdiagnosed case (LYG/O, d), the net prevented LC deaths subtracted by
the number of overdiagnosed cases (D-O, e), and the number of LC deaths prevented per overdiagnosis risk (D/(O/S), f). Within each met-
ric, a consensus scenario was identified by choosing a scenario that is defined as an “efficient scenario” (i.e. top 25% closest scenarios to
the efficient frontier) by at least three out of the four models under each metric. The consensus scenarios are listed in the legend box and
highlighted for a representative model. For each panel, the NLST-like and the USPSTF scenarios are plotted for reference purposes, regard-
less of whether or not they are included in the consensus list. The results for females are shown in Supporting Information Figures 5 and
6. Each legend box shows the scenarios selected by consensus across the four models and annotated as Frequency–Start Age (y)–Stop
Age (y)–Pack-Years–Years Since Quitting.
overdiagnosis cases over a wide range of screening scenarios.
In comparison with screening programs for other cancers
such as prostate cancer and breast cancer which have been
estimated to have D/O values less than one (0.2 for prostate
cancer17 and 0.3 for breast18), our results suggest that the nega-
tive impact of screening could be lower for LC compared to
screening for other cancers. However, morbidity and mortality
associated with overdiagnosis of LC may be higher than those of
other cancer hence a direct comparison of overdiagnosis-related
outcomes across different cancers is not warranted.
Our model-based approach for analyzing overdiagnosis in
lung cancer screening has several advantages compared to a
trial data based approach. Recently an upper bound of the
overdiagnosis risk of 18.5% for LC was estimated based on
excess incidence using the NLST data.2 This estimate is an
upper bound because it quantifies the excess incidence
observed in the CT arm compared to the chest X-ray arm
after a short follow-up period (8 years from trial entry), and
likely includes screen-detected cases that would have been
clinically detected. Longer follow-up would be needed to
observe “catch-up” cancers in the control arm to allow a
more accurate estimate of overdiagnosis based on excess inci-
dence.19,20 A trial-derived estimate of the overdiagnosis risk
would be of limited generalizability even if based on a suffi-
cient follow-up period because the estimate would be associ-
ated with the specific screening strategy of the trial. For
example, most participants in NLST were screened annually
for 3 years and aged between 55 and 74 with at least 30
pack-years smoking and <15 years since they quit smoking
at the time of enrollment. However, different screening strat-
egies (e.g. variations in smoking, stopping age or screening
frequency) would likely yield different overdiagnosis risks.
Given of all these challenges, a model-based approach is
valuable for estimating overdiagnosis in a lifetime screening
by providing insights into how different screening strategies
affect overdiagnosis.
While our overdiagnosis analyses across numerous screen-
ing scenarios could not be performed without modeling,
Table 1. Consensus scenarios chosen by maximizing the number of prevented LC deaths (D); and the number of prevented LC deaths per
overdiagnosed case (D/O). [Color table can be viewed at wileyonlinelibrary.com]
Metric
Efficient scenario
frequency–start
age (y)–stop age
(y)–pack-years–years
since quitting
No. CT
scans
Overdiagnosis
(%)
No.
overdiagnosed
cases (O)
No.
prevented
LC deaths
(D)
Mortality
reduction
(%)
Life-years
saved D/O
Female A-55-80-40-25 166177 13.82 241 453 14.6 5983 2.56
A-60-80-20-10 186932 12.29 224 456 14.7 5889 2.74
A-60-80-30-20 189433 13.55 264 480 15.7 6212 2.55
D A-60-80-30-25 208614 13.69 290 510 16.9 6593 2.47
A-60-80-20-15 227049 12.81 272 527 17.6 6833 2.65
A-55-80-30-15 232461 12.5 239 528 17.7 7342 2.94
A-60-80-10-15 261556 12.77 281 551 18.3 7209 2.69
A-55-75-30-10 186549 9.98 145 422 13.6 6194 3.56
A-55-75-30-15 214158 10.28 166 466 15.3 6831 3.45
D/O A-55-75-30-20 235702 10.39 180 495 16.5 7340 3.48
A-55-75-30-25 250305 10.49 189 512 17.2 7616 3.46
A-55-75-20-10 253105 9.66 169 504 16.9 7350 3.63
Male A-55-80-40-25 260832 11.78 256 526 14.2 7700 2.70
A-60-80-30-20 261778 11.88 277 528 14.2 7122 2.55
D A-55-80-30-10 286878 11.2 250 547 14.7 7936 2.87
A-60-80-30-25 287521 11.89 294 563 15.2 7616 2.58
A-60-80-20-20 307380 11.77 288 561 15.3 7779 2.57
A-55-80-30-15 326549 11.21 270 597 16.3 8698 2.90
A-55-75-30-10 267730 9.13 180 498 13.2 7513 3.55
D/O A-55-75-30-15 301853 9.12 192 536 14.4 8170 3.54
A-55-75-20-10 312252 9.09 186 532 14.3 8164 3.57
A-55-75-30-20 330807 9.02 200 566 15.4 8679 3.60
A consensus scenario was identified by choosing a scenario that is defined as an “efficient scenario” (i.e. top 25% closest scenarios to the efficient
frontier) by at least three out of the four models. For the numbers in each cell below, model average values were used. The USPSTF scenario and
NLST-like scenarios are highlighted in red and blue, respectively. Grayed scenarios are the ones that overlap between genders within each metric.
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modeling has limitations. Firstly, we found that the absolute
values of the overdiagnosis risks vary across the four models.
This variation is due in part to the fact that the four models
were developed independently based on different assump-
tions, datasets, and mathematical formulations. Given these
differences, the model variation captures a range of uncer-
tainty associated with model building that could not be cap-
tured by one model alone. However, despite this model
variation, relative magnitudes of overdiagnosis risks and
related statistics such as D/O were notably consistent across
the models. For example, overdiagnosis was larger in the
USPSTF scenario than in the NLST-like scenario in all four
models, as was D/O in the NLST-like scenario compared to
the USPSTF. Second, while we accounted for smoking-related
effects on other cause mortality, we assumed that screening
was performed on any individual who met the smoking and
age criteria without explicit consideration of existing co-
morbidities. A screen detected cancer patient with significant
co-morbidities is more likely to be overdiagnosed than one
without significant co-morbidities, because the patient with
comorbidities has a higher competing risk of death. As addi-
tional data becomes available to associate other cause mortal-
ity with co-morbidities in screening eligibility, the risk of
overdiagnosis will likely to decrease. Third, our study
assumed perfect screening compliance but if screening com-
pliance reduces at the older ages, then overdiagnosis risks
will decrease. Fourth, our analysis is based on calibrations to
the practice patterns of NLST; should practice patterns
change, particularly for the management of small indetermi-
nant nodules on CT, our D/O estimates would need to be
modified. Finally, our study evaluated hypothetical screening
strategies that vary by age, smoking, and screening frequency
as considered in the USPSTF guidelines, but we did not vary
other factors such as nodule size or screening results that
may also have impacts on LC mortality or overdiagnosis.
Our future research includes the evaluation of efficient diag-
nostic work up strategies by varying several factors for
follow-up, such as nodule size, features, follow-up interval,
use of biomarkers, and prior screening results to examine
how these factors affect the benefits and harms of CT in the
population setting.
In summary, our model-based analysis shows that incor-
porating overdiagnosis affects the selection of efficient screen-
ing strategies. Consistent results across four independent
models indicate that our findings are robust. We conclude
that while screening through age 80 is efficient in reducing
LC mortality irrespective of overdiagnosis, stopping screening
at a younger age of 75 provides a greater efficiency in reduc-
ing LC deaths and increasing life-years gained per overdiag-
nosed case, which merit further consideration when
balancing the benefits and harms of screening.
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